Description
GNE-7915 is an inhibitor of leucine-rich repeat kinase 2 (LRRK2). GNE-7915 exhibits neuroprotective activity and is in development as a potential treatment for neurodegenerative disorders such as Parkinson’s disease.
| Product Unit Size | Cost | Quantity | Stock |
|---|
GNE-7915 is an inhibitor of leucine-rich repeat kinase 2 (LRRK2). GNE-7915 exhibits neuroprotective activity and is in development as a potential treatment for neurodegenerative disorders such as Parkinson’s disease.
| Cas No. | 1351761-44-8 |
|---|---|
| Purity | ≥98% |
| Formula | C19H21F4N5O3 |
| Formula Wt. | 443.40 |
| IUPAC Name | (4-{[4-(Ethylamino)-5-(trifluoromethyl)-2-pyrimidinyl]amino}-2-fluoro-5-methoxyphenyl)(4-morpholinyl)methanone |
| Synonym | GNE7915 |
| Solubility | DMSO 22 mg/mL warmed (49.61 mM) Water Insoluble Ethanol Insoluble |
| Appearance | White Crystal Powder |
| Store Temp | -20°C |
|---|---|
| Ship Temp | Ambient |
| MSDS | |
|---|---|
| Info Sheet | |
| Brochures |
Kavanagh ME, Doddareddy MR, Kassiou M. The development of CNS-active LRRK2 inhibitors using property-directed optimisation. Bioorg Med Chem Lett. 2013 Jul 1;23(13):3690-6. PMID: 23721803.
Estrada AA, Liu X, Baker-Glenn C, et al. Discovery of highly potent, selective, and brain-penetrable leucine-rich repeat kinase 2 (LRRK2) small molecule inhibitors. J Med Chem. 2012 Nov 26;55(22):9416-33. PMID: 22985112.
Dihydropyridine; L-type and N-type Ca2+ channel...
EZH2 HMT inhibitor.
Bumetanide impurity
PI3K and mTOR inhibitor.
TTK/CLK2 inhibitor.
Building block
β2-adrenergic agonist.
ATR inhibitor.
Fluoroquinolone; topoisomerase IV and bacterial...
Found in Streptomyces; proteasome inhibitor.
Peptide; NMDA partial agonist.
Triterpene saponin originally found in Bolboste...
Endogenous pteridine metabolite of GTP.
PLK1 inhibitor.
ANP analog, cardiomodulatory peptide; NPR-A ago...
Mycotoxin produced by Aspergillus; carcinogen.<...
Peptide toxin found in Conus snails; nAChR inhi...
Coccidiostat.